


Guidelines of the Polish Society of Gynecologists and Obstetricians on the diagnosis and treatment of iron deficiency and iron deficiency with anemia

Piotr Sieroszewski¹, Dorota Bomba-Opon², Wojciech Cnota³, Agnieszka Droszol-Cop⁴, Marek Gogacz⁵, Mariusz Grzesiak⁶, Hubert Huras⁷, Artur Jakimiuk⁸, Piotr Kaczmarek⁶, Sebastian Kwiatkowski⁹, Radzislaw Mierzynski¹⁰, Włodzimierz Sawicki¹¹, Agnieszka Seremak Mrozikiewicz¹², Rafal Stojko⁴, Mirosław Wielgos¹³, Ewa Wender-Ozegowska¹⁴, Mariusz Zimmer¹⁵, Marta Konieczna¹⁶

¹1st Department of Gynaecology and Obstetrics, Medical University of Lodz, Poland

²1st Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland

³Chair and Department of Gynaecology and Obstetrics in Ruda Slaska, Medical University of Silesia in Katowice, Poland

⁴Chair and Department of Gynecology, Obstetrics and Oncological Gynecology, Medical University of Silesia in Katowice, Poland

⁵2nd Department of Gynecology, Medical University of Lublin, Poland

⁶Department of Perinatology, Obstetrics and Gynaecology, Polish Mother's Memorial Hospital Research Institute in Lodz, Poland

⁷Collegium Medicum, Jagiellonian University, Cracow, Poland

⁸Department of Obstetrics and Gynecology, Central Clinical Hospital of the Ministry of the Interior and Administration (MSWiA), Warsaw, Poland

⁹Department of Obstetrics and Gynecology, Pomeranian Medical University in Szczecin, Poland

¹⁰Chair and Department of Obstetrics and Perinatology, Medical University of Lublin, Poland

¹¹Chair and Department of Obstetrics, Gynecology and Gynecological Oncology, Medical University of Warsaw, Poland

¹²Department of Perinatology and Women's Diseases, Poznan University of Medical Sciences, Poznan, Poland

¹³1st Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland

¹⁴Department of Reproduction, Chair of Obstetrics, Gynecology and Gynecological Oncology, Poznan University of Medical Sciences, Poland

¹⁵2nd Department of Gynecology and Obstetrics, Wrocław Medical University, Poland

¹⁶Pathology of Pregnancy Department Medical University of Lodz, Poland

Guidelines of the Polish Society of Gynecologists and Obstetricians present the most up-to-date treatment and management recommendations, which may be modified and altered after detailed analysis of a specific clinical situation, which in turn might lead to future modifications and updates.

INTRODUCTION

According to the World Health organization (WHO), anemia affects approximately 30% of the global population. In the developing countries, anemia is diagnosed in every second pregnant woman [1]. Iron deficiency remains the most common cause of anemia in pregnancy (approximately 60–80% of the cases) [2], which in turn causes impaired iron synthesis and is characterized by the appearance of erythrocyte population with low hemoglobin count and content.

The acceptable norm for hemoglobin (Hb) concentration in healthy individuals depends on the investigated population. Obstetric and gynecologic causes of iron-deficiency anemia (IDA) in women include puberty, pregnancy and lactation (insufficient supply due to increased demand), menorrhagia, endometrial polyps, uterine myomas and uterine tumors, as well as other abnormal bleedings (increased blood loss).

Corresponding author:

Piotr Sieroszewski

¹1st Department of Gynaecology and Obstetrics, Medical University of Lodz, Poland

e-mail: sieroszewski@gmail.com

Received: 30.11.2022 Accepted: 30.11.2022 Early publication date: xx.xx.2022

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

The symptoms of iron deficiency and IDA include difficulty concentrating, irritability, palpitations, the Pica syndrome (cravings for clay, chalk, starch), sore, inflamed and smooth surface of the tongue, skin dryness, painful and cracked corners of the mouth, changes in the nail plate (paleness, fragility, ridges) and hair (thinning strands, brittleness, split ends, hair loss). Importantly, the spectrum of the symptoms varies between the individual cases [3].

In the absence of Polish recommendations, the Polish Society of Gynecologists and Obstetricians issued their own guidelines concerning the diagnostic process and treatment of anemia and iron deficiency in pregnant and reproductive-age women.

IRON DEFICIENCY

Iron requirements vary throughout human life and depend on age, sex, and the overall health condition. In adult females, daily requirement is 2 mg, but the demand changes during pregnancy and breastfeeding: 1–2.5 mg in the first trimester and 6.5 mg/day in the third trimester [4, 5]. Iron deficiency occurs when the iron content in the body fails to meet the current demand, but iron deficiency is not always equivalent to anemia. Iron deficiency may be pre-latent, latent and symptomatic (with anemia) [3, 6] (Tab. 1).

Ferritin serves as storage for iron, but it is also an acute-phase reactant, so ferritin levels rise as an immune response to inflammation. The lower range of normal ferritin levels in an inflammatory state is 100 mcg/L. Additionally, transferrin saturated with iron (TSAT) levels might be useful in the process of diagnosis as any result of < 20% will be indicative of iron deficiency [3].

DIAGNOSTICS

Iron deficiency is caused by significant blood loss, an increase in demand but inadequate supply, malabsorption,

poor dietary intake, genetic treatment-resistant iron deficiency anemia. Complete blood count (CBC) is a simple, inexpensive and easily available test which is used as the first-choice tool in the diagnostic process of anemia.

The following iron parameters should be used to differentiate the causes of anemia:

- serum ferritin levels;
- serum iron levels;
- total iron-binding capacity (TIBC);
- transferrin saturation (TSAT), iron concentration $\times 100/\text{TIBC}$ (normal values 20–50%).

Additional recommended tests include measuring serum vit. B12 and folic acid levels.

In accordance with the Management of Physiological Pregnancy Standards based on the Ministry of Health regulation, CBC is recommended at the first prenatal visit, and at 15–20, 27–32, 33–37 and 38–39 weeks of gestation. Apart from CBC, the Polish Society of Gynecologists and Obstetricians recommends to also measure ferritin levels at the first prenatal visit, especially in case of anemia to differentiate the underlying cause. Routine CBC is recommended once a year in all healthy women [7] (Fig. 1, Tab. 2).

TREATMENT

Treatment of anemia should identify its cause as anemia itself is merely a symptom. In IDA, iron replacement therapy (IRT) and, in extreme cases, transfusion therapy using erythrocyte concentrate are used. The route of administration should be modified, depending on the clinical condition, test results, and patient response to treatment. The possible routes include oral as well as parenteral (intravenous and intramuscular) IRT.

ORAL IRON REPLACEMENT THERAPY

The oral route is recommended in mild IDA, when Hb levels exceed 9 g/dL. The benefits of oral IRT include ease of

Table 1. Stages of iron deficiency in women

Parameter	Norm	Pre-latent	Latent	Symptomatic with anemia
		Lowered levels of serum ferritin and bone marrow iron stores	Significantly lowered ferritin concentration, lowered serum and bone marrow iron levels, low tsat values, but high transferrin and soluble transferrin receptor levels, hb and mcv are normal	Significantly lowered ferritin concentration, lowered serum and bone marrow iron levels, low tsat values, while transferrin and soluble transferrin receptor levels rise; hb and mcv concentrations drop
Ferritin	30–200 mcg/L	< 30 mcg/L	< 12 mcg/L	< 30 mcg/L, as in pre-latent stage
Serum iron	55–180 mcg/L	55–180 mcg/L	< 55 mcg/L	< 55 mcg/L
Hb	≥ 12 g/dL ≥ 11 g/dL in pregnancy ≥ 10 g/dL postpartum	≥ 12 g/dL ≥ 11 g/dL in pregnancy ≥ 10 g/dL postpartum	≥ 12 g/dL ≥ 11 g/dL in pregnancy ≥ 10 g/dL postpartum	< 12 g/dL < 11 g/dL in pregnancy < 10 g/dL postpartum
MCV	82–92 fL	82–92 fL	82–92 fL	< 82 fL
Transferrin	2–4 g/L	> 4 g/L	> 4 g/L	> 4 g/L

Hb — hemoglobin; MCV — *mean corpuscular volume*; TSAT — transferrin saturated with iron




Figure 1. Algorithm for causes of anemia; MCV — mean corpuscular volume; Hb — hemoglobin

Table 2. Differentiation between iron deficiency, iron-deficiency anemia and anemia of chronic disease			
Parameter	iron deficiency	iron-deficiency anemia	Anemia of chronic disease
Hb	N	↓ different levels	Hb < 9 g/dL — rarely
MCV	N	↓	N or ↓
Serum ferritin	↓	↓	↑ or less often N
TIBC	↑	↑	↓
TSAT	↓	↓	N or ↓
Serum iron	↓	↓↓	↓ or less often N

↓ decreased concentration/value, ↑ increased concentration/value

Hb — hemoglobin; MCV — mean corpuscular volume; N — normal concentration/value; TIBC — total iron-binding capacity; TSAT — transferrin saturated with iron

administration and the fact that the patient does not require assistance during administration. Oral iron preparations can be divided into iron (II) and iron (III), depending on its oxidation state.

Oral iron preparations which are available in Poland include:

- complex of iron(III) hydroxide and poli-isomaltose;
- iron (II) sulphate;
- iron (II) fumarate;
- iron (II) gluconate;
- iron (III) protein succinylate.

Iron is absorbed in the duodenum and the small intestine, mainly as reduced iron (II). The acidic environment of the gastric and ascorbic acid prevents earlier iron oxidation. On entering the enterocyte, iron is translocated to blood plasma, where it binds to transferrin. Part of the iron binds with apoferritin in the intestinal mucosa epithelium, forming ferritin, which is the circulating iron reserve. Iron (III) is transported and stored, while iron (II) is contained in hemoglobin [8–10].

Pregnant women

According to the WHO criteria, hemoglobin concentration of < 11 g/dL in each of the trimesters and < 10 g/dL during the puerperium is considered anemia in pregnancy [11]. Similar criteria have been suggested by the Centers for Disease Control and Prevention (CDC), which define iron-deficiency anemia in pregnancy as Hb concentration of 11 g/dL in the first and third trimester and 10.5 g/dL in the second trimester [12].

Likewise, the Polish Society of Gynecologists and Obstetricians recommends establishing the threshold value for anemia at 11 g/dL in all trimesters and 10 g/dL in the puerperium.

Since 12 weeks of gestation, plasma volume expansion achieves a 40–60% increase, even 70–100% in multiple pregnancy, which is the cause of physiological anemia of pregnancy (relative expansion of the plasma volume in comparison to hematopoietic cells). The levels of hemoglobin and hematocrit drop by 3–5% to 36 weeks of gestation [13, 14].

Iron deficiency may increase the risk for premature labor, infection, low birthweight and perinatal complications [1, 15].

In non-anemic pregnant women, with ferritin concentrations < 60 mcg/L after 16 weeks of gestation, it is recommended to replace iron at a maximum daily dose of up to 30 mg. The rationale behind it is that iron overload is detrimental to the human body as it generates reactive oxygen species [7]. The probability of IDA is lower if ferritin concentration ranges from 60 to 70 mcg/L.

Women with non-anemic iron deficiency are recommended a daily dose of 65 mg elemental iron. In IDA, a daily dose of 60–200 mg elemental iron is recommended [9]. Hemoglobin and ferritin levels should be measured two weeks after therapy commencement to evaluate patient response to treatment – absorption of that form of iron in the body.

Once normal Hb level is achieved, the treatment needs to be continued for three months and for at least six weeks postdelivery to replace iron deficiency. Preparations with higher bioavailability and differential diagnosis to detect the cause for anemia are recommended in patients who are non-responsive to oral IRT.

Unfavorable consequences of iron overload include:

- development of insulin resistance and decreased insulin secretion by pancreatic β -cells [16, 17];
- increased risk for developing preeclampsia, especially in women supplementing iron before 16 weeks of gestation without decreased hemoglobin levels (Hb > 13.2 g/dL at the beginning of the second trimester) [18, 19];
- development of gestational diabetes [20, 21] (Tab. 3).

Non-pregnant women

Anemia in non-pregnant women, regardless of their age, is defined as Hb levels of < 12 g/dL [22, 23]. Routine CBC is recommended in healthy women at least once a year.

Table 3. Consequences of iron deficiency and iron overload

iron deficiency — increased risk for:

- premature labor
- infection
- low birthweight
- perinatal complications
- central nervous system abnormalities in the fetus

iron overload — increased risk for:

- insulin resistance and decreased insulin secretion by pancreatic β -cells
- preeclampsia
- gestational diabetes

Special steps should be taken to address iron deficiency in women who are about to undergo surgery due to gynecological reasons (*e.g.*, uterine myomas, endometrial hyperplasia, gynecologic malignancy, *etc.*), to avoid transfusions during the postoperative period and improve healing and convalescence.

If anemia is diagnosed, oral IRT with a single (or split in two) daily dose of 60–200 mg elemental iron is recommended.

An increase in the reticulocyte count after 7 days and in Hb concentration by app. 2 g/dL after 2 weeks since therapy commencement is indicative of treatment efficacy. The treatment should be continued until normal Hb and ferritin concentrations are achieved, typically for min. 3 months after normalization of Hb levels.

General comments

Iron preparations should be taken on an empty stomach, if possible, and not combined with other medicines such as antacids calcium supplements, H_2 receptor antagonists, or tetracyclines as these drugs lower iron absorption. The longest possible time interval between administration of these medicines and iron IRT is recommended.

According to Campbell, a daily dose of 250 mg vit. C might improve absorption from the digestive system as iron absorption is more effective in acidic environment [24]. Still, the effects of IRT combined with vit. C to improve iron absorption remains to be fully elucidated [25].

Attention should be paid to differences in elemental iron content in the available preparations.

Resistance to treatment with iron (II) oral preparations is defined as lack of an increase in Hb concentration by > 1 g/dL after 4–6 weeks of IRT with a daily dose of 100 mg iron. Resistance may be the result of chronic bleeding, malabsorption, misdiagnosis, or patient non-compliance [3]. If the response to oral IRT is poor, other factors which might contribute to the anemia — folate deficiency, vitamin B12 deficiency, anemia of chronic diseases or low-iron anemia caused by iron loss from the digestive tract (*e.g.*, IBD) which are often observed in pregnancy — should be investigated.

Iron preparations for oral IRT have adverse effects mainly on the gastrointestinal system and include nausea, emesis and constipation. In order to avoid the abovementioned side effects, a smaller (gradually increasing) dose or change of iron preparation is recommended.

The presence of side effects is not an indication to discontinuation of IRT. Contraindications to IRT include iron overload, other types of anemia without iron deficiency, or acute infection.

Interactions between certain groups of medicines with oral iron supplements are presented in Table 4.

Table 4. Interactions between certain groups of medicines with oral iron supplements

Medicines	Interactions	Recommendations
Antacids	↓ iron absorption	The longest possible time interval between these medicines is advised
Calcium supplements	↓ iron absorption	The longest possible time interval between these medicines is advised (min. 2 hours)
H₂ receptor antagonists	↓ iron absorption	At least 1 hour interval between oral iron preparation and H ₂ receptor antagonist
Tetracyclines	↓ iron and tetracycline absorption	Tetracycline should be administered 3 hours after or 2 hours before oral iron preparation
Intravenous iron preparations	↑ iron toxicity	Concurrent administration of oral and intravenous preparations is not advised
Methyldopa	↓ methyldopa absorption, decreased hypotensive activity	BP should be monitored
Penicillamine	↓ penicillamine absorption	A min. 2 hour-interval is advised
Thyroxine	↓ thyroxine absorption	A min. 2 hour-interval is advised; thyroid function should be monitored
Vitamin C	↑ iron absorption	Concurrent supplementation with vit. C and iron preparations may be beneficial

INTRAVENOUS IRON REPLACEMENT THERAPY

Intravenous IRT is recommended in cases when oral supplementation proves to be ineffective and iron content cannot be replaced over 1–3 months (malabsorption, iron loss which exceeds absorption capacity, intolerance of oral preparations, non-compliant patients), and if Hb levels are 7–9 g/dL in pregnancy, in the second and third trimester, and in non-pregnant women.

Parenteral route should be considered since the second trimester of pregnancy and during the puerperium in women with IDA who are not responsive to oral IRT, are intolerant of the oral route, or in cases when Hb levels range from 7 to 9 g/dL.

Intravenous iron preparations available in Poland include:

- iron (III)-hydroxide sucrose complex (ferric gluconate);
- iron (III)-hydroxide dextran complex;
- ferric carboxymaltose;
- iron (III)-derisomaltose.

All the above mentioned intravenous iron preparations are equally effective in treating IDA and have a similar safety profile. The main differences are associated with the number of injections and time required to administer the full dose, as well as administration costs (Tab. 5).

Several authors have presented their experience with parenteral iron therapy to treat IDA and reported faster increase of Hb levels and better repletion of the iron storage as compared to oral administration. Satisfactory effects of intravenous iron preparations were demonstrated especially in the case of iron sucrose [28] and ferric carboxymalt-

ose (III) [29]. A large retrospective study reported a lower number of postdelivery transfusions in women receiving intravenous IRT [30].

Possible complications of intravenous IRT include:

- anaphylactic reaction,
- hypophosphatemia — as a result of increased urinary phosphate excretion caused by elevated serum FGF-23 (fibroblast growth factor 23) levels, followed by decreased levels of circulating 1,25-dihydroxyvitamin D [31],
- non-allergic reactions to the infusion (manifesting as self-limiting urticaria, palpitations, dizziness, neck and back spasms in < 1% of the affected individuals) typically do not lead to more serious reactions [32],
- complement activation-related pseudo-allergy (CARPA), manifesting as facial redness, chest and back pains, known as the Fishbane reactions [33, 34]. Intravenous IRT in patients with active infection should be delayed until symptom resolution [35].

INTRAMUSCULAR IRON REPLACEMENT THERAPY

Intramuscular IRT offers an alternative to intravenous route, but it is not the method of choice as far as iron supplementation is concerned. Iron (III)-hydroxide dextran complex is the only intramuscular iron preparation available in Poland. The injections are painful and associated with high risk for permanent skin discoloration, so intramuscular route is not recommended [36]. If it is necessary, the Z-track method for intramuscular injections is recommended to minimize the risk for iron transmission to the skin. The Z-track method is used to avoid injection or seeping of the injected sub-

Table 5. Comparison of intravenous iron supplements available in Poland* [27]

	Iron (III)-hydroxide dextran complex	Iron (III)-hydroxide sucrose complex	Ferric carboxymaltose	Iron (III)-derisomaltose
Test dose	Before every intravenous administration; one time before intramuscular administration	Only once, in new patients	Not necessary	Not required
Route of administration	Slow infusion	Slow infusion	intravenous administration over 15 min.	Slow infusion
Total daily dose	Up to 20 mg/kg of body weight for 4–6 hours	Single dose, not more than 200 mg, may be repeated 3 times/week	Up to 20 mg/kg (max. 1000 mg/week)	Up to 20 mg/kg for 1 hour
Half-life	5 hours	20 hours	7–12 hours	24–96 hours
Dosing	100–200 mg 2–3 times/week, depending on Hb concentration (up to the max. dose — 20 mg/kg)	Single dose, not higher than 200 mg, may be repeated 3 times/week	1. Intravenous injection of non-diluted solution. The maximum single dose: 15 mg iron/kg body weight. 2. Intravenous infusion diluted in 0.9% m/V sterile sodium chloride. The maximum single dose: 20 mg iron/kg weight	1. Bolus iv injection at a dose of up to 500 mg up to 3 times/ week. 2. IV drip infusion : — single infusion at a dose of up to 20 mg iron /kg body weight / week — directly into the venous limb of the dialyzer, the same procedure as iv bolus injection
Pregnancy	Contraindicated in the first trimester	Contraindicated in the first trimester	Contraindicated in the first trimester	Contraindicated in the first trimester
Lactation	Unknown risk	Transfer into breast milk is unlikely, no clinical trials	< 1% transfers to breast milk, insignificant	Unknown risk
Adverse effects	5% of patients — min. adverse effects, Risk of anaphylaxis < 1/10000. Risk of allergic reaction > 1/1000 < 1/100	0.5–1.5% of patients – adverse effects, Risk of anaphylaxis > 1/10000 < 1/1000	3% of patients — adverse effects; hypersensitivity: > 1/1000 to < 1/100; pseudo-anaphylactic/ anaphylactic reactions: > 1/10000 to < 1/1000	> 1% of patients — adverse effects; Risk of anaphylaxis ≥ 1/10 000 to < 1/1000; Risk of allergic reaction ≥ 1/1000 to < 1/100

*based on the Summary of Product Characteristics (SmPC)

stance into the subcutaneous tissue. During the procedure, the skin and tissue are pulled in the direction away from the site of the injection.

BLOOD TRANSFUSION

In patients with life-threatening (Hb levels < 7 g/dL) anemia due to causes other than iron deficiency causes, transfusion of compatible erythrocyte concentrate is recommended. The decision to transfuse erythrocyte concentrate should not be based solely on the hemoglobin level but also on the clinical condition of the patient (*e.g.*, risk for further bleeding). In the case of acute blood loss and hypovolemic shock, timely red blood cell transfusion is a life-saving procedure. In such cases, hemodynamic disturbance is the indication for the transfusion and the decision needs to consider the actual and potential future blood loss. Such

management aims to quickly restore the erythrocyte volume of the circulating blood.

Transfusion-related complications include:

- anaphylactic reaction,
- life-threatening hemolysis,
- transfusion-related acute lung injury (TRALI),
- febrile reactions,
- urticaria and other skin reactions [3].

The risk of red blood cell alloimmunization and the potential clinical benefits of red blood transfusion should be considered. Women deemed eligible for erythrocyte concentrate transfusion need to be fully informed about the indications for transfusion and the available alternatives. Written informed consent must be obtained from the patient and the entry about blood transfusion should be made in the patient medical records.

Table 6. Threshold Hb values to determine the route of administration in pregnant and non-pregnant women

Oral preparation	Intravenous preparation	Blood transfusion
Hb < 12 g/dL in women Hb < 11 g/dL in pregnancy Hb < 10 g/dL in puerperium	Hb 7–9 g/dL Hb in pregnancy 7–9 g/dL in the second and third trimester	Hb ≤ 7 g/dL

Hb — hemoglobin

ALTERNATIVE METHODS OF TREATING ANEMIA

Erythropoietin preparations

In case of persistent anemia — despite treatment — in pregnant women with chronic renal disease (diabetic nephropathy or history of renal transplant), administration of erythropoietin preparations might be considered as these women present with renal anemia. The available preparations include recombinant human erythropoietin or darbepoetin. Darbepoetin alpha is a unique erythropoiesis-stimulating protein, which may be administered at prolonged intervals as compared to recombinant human erythropoietin as its serum half-life is app. 3-fold longer [37].

SUMMARY

- Oral iron administration is the first-line of treatment in mild IDA, when Hb concentration exceeds 9 g/dL.
- Iron supplementation in pregnant women at the daily dose of up to 30 mg should be recommended only to non-anemic women, with ferritin levels over 60 mcg/L after 16 weeks of gestation.
- Women with non-anemic iron deficiency should receive a daily dose of 65 mg elemental iron. In IDA, the initial daily dose of 60–200 mg elemental iron is recommended.
- Intravenous IRT is recommended in cases with Hb concentrations of 7–9 g/dL in pregnancy in the second and third trimester, and of < 10 g/dL during the puerperium, as well as in the absence of patient response to oral IRT.
- Most adverse effects in intravenous IRT are not in fact anaphylactic reactions (*e.g.*, Fishbane reactions).
- Intramuscular route may be considered as an alternative to intravenous IRT, but it is not the preferred route due to the possible complications.
- Erythrocyte concentrate transfusion is recommended in cases of life-threatening anemia or when Hb levels are < 7 g/dL (Tab. 6).

CONCLUSIONS

- Iron deficiency is a global health problem.
- Symptoms of iron deficiency anemia may appear in cases of non-anemic iron deficiency.
- Route of administration of the iron preparations in cases with anemia should depend on test results (Hb concen-

tration, ferritin, TSAT) and clinical state of the affected patients.

Conflict of interest

All authors declare no conflict of interest.

REFERENCES

1. WHO/UNU/UNICEF, Iron deficiency anaemia. Assessment, prevention and control. A guide for programme managers. World Health Organization. Geneva, 2001.
2. WHO, The Global Prevalence of Anaemia in 2011; World Health Organization, 2015.
3. Podolak-Dawidziak M. Niedokrwistości. In: Gajewski P. ed. Interna Szczeklika. Medycyna Praktyczna, Kraków 2017: 1711–1736.
4. Steer PJ. Maternal hemoglobin concentration and birth weight. *Am J Clin Nutr.* 2000; 71(5 Suppl): 1285S–1287S, doi: [10.1093/ajcn/71.5.1285s](https://doi.org/10.1093/ajcn/71.5.1285s), indexed in Pubmed: [10799403](https://pubmed.ncbi.nlm.nih.gov/10799403/).
5. Milman NT. Dietary iron intake in pregnant women in Europe: a review of 24 studies from 14 countries in the period 1991–2014. *J Nutr Metab.* 2020; 2020: 7102190, doi: [10.1155/2020/7102190](https://doi.org/10.1155/2020/7102190), indexed in Pubmed: [32185079](https://pubmed.ncbi.nlm.nih.gov/32185079/).
6. Balendran S, Forsyth C. Non-anaemic iron deficiency. *Aust Prescr.* 2021; 44(6): 193–196, doi: [10.18773/austprescr.2021.052](https://doi.org/10.18773/austprescr.2021.052), indexed in Pubmed: [35002031](https://pubmed.ncbi.nlm.nih.gov/35002031/).
7. Zimmer M, Sieroszewski P, Oszukowski P, et al. Polish Society of Gynecologists and Obstetricians recommendations on supplementation in pregnancy. *Ginekol Pol.* 2020; 91(10): 644–653, doi: [10.5603/gp.2020.0159](https://doi.org/10.5603/gp.2020.0159), indexed in Pubmed: [33184834](https://pubmed.ncbi.nlm.nih.gov/33184834/).
8. World Health Organization. Preventing and controlling iron deficiency anaemia through primary health care. A guide for health administrators and programme managers. World Health Organization, Geneva 1989.
9. Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. *Am Fam Physician.* 2013; 87(2): 98–104, doi: [afp/2013/0115/afp20130115p98](https://doi.org/10.2531/afp20130115p98).
10. Myśliwiec M. Doustna suplementacja żelaza w niedokrwistości nerkopochodnej. *Forum Nefrologiczne.* 2012; 5(3): 195–203.
11. World Health Organization, Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. World Health Organization, 2011.
12. Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. *MMWR Recomm Rep.* 1998; 47(RR-3): 1–29, indexed in Pubmed: [9563847](https://pubmed.ncbi.nlm.nih.gov/9563847/).
13. Lind T. Maternal Physiology: CREOG Basic Science Monograph in Obstetrics and Gynecology. Council on Resident Education in Obstetrics and Gynecology, Washington D.C. 1985.
14. Rozporządzenie Ministra Zdrowia z dnia 16 sierpnia 2018 r. w sprawie standardu organizacyjnego opieki okołoporodowej. <https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20180001756> (12.11.2022).
15. Liu D, Li S, Zhang B, et al. Maternal hemoglobin concentrations and birth weight, low birth weight (LBW), and small for gestational age (SGA): findings from a prospective study in northwest china. *Nutrients.* 2022; 14(4): 858, doi: [10.3390/nu14040858](https://doi.org/10.3390/nu14040858), indexed in Pubmed: [35215507](https://pubmed.ncbi.nlm.nih.gov/35215507/).
16. Hansen JB, Tonnesen MF, Madsen AN, et al. Divalent metal transporter 1 regulates iron-mediated ROS and pancreatic β cell fate in response to cytokines. *Cell Metab.* 2012; 16(4): 449–461, doi: [10.1016/j.cmet.2012.09.001](https://doi.org/10.1016/j.cmet.2012.09.001), indexed in Pubmed: [23000401](https://pubmed.ncbi.nlm.nih.gov/23000401/).
17. Hansen JB, Moen IW, Mandrup-Poulsen T. Iron: the hard player in diabetes pathophysiology. *Acta Physiol (Oxf).* 2014; 210(4): 717–732, doi: [10.1111/apha.12256](https://doi.org/10.1111/apha.12256), indexed in Pubmed: [24521359](https://pubmed.ncbi.nlm.nih.gov/24521359/).

18. Maitra S, Mukthapuram A, Huligol G, et al. Increased Serum Ferritin and Iron Levels in Preeclampsia. *IOSR-JBB*. 2019; 5(2): 50–52, doi: [10.9790/264X-0502015052](https://doi.org/10.9790/264X-0502015052).
19. Shaji Geetha N, Bobby Z, Dorairajan G, et al. Increased hepcidin levels in preeclampsia: a protective mechanism against iron overload mediated oxidative stress? *J Matern Fetal Neonatal Med*. 2022; 35(4): 636–641, doi: [10.1080/14767058.2020.1730322](https://doi.org/10.1080/14767058.2020.1730322), indexed in Pubmed: [32079434](https://pubmed.ncbi.nlm.nih.gov/32079434/).
20. Kataria Y, Wu Y, Horskjær Pd, et al. Iron status and gestational diabetes - a meta-analysis. *Nutrients*. 2018; 10(5): 621, doi: [10.3390/nu10050621](https://doi.org/10.3390/nu10050621), indexed in Pubmed: [29762515](https://pubmed.ncbi.nlm.nih.gov/29762515/).
21. Helin A, Kinnunen TI, Raitanen J, et al. Iron intake, haemoglobin and risk of gestational diabetes: a prospective cohort study. *BMJ Open*. 2012; 2(5): e001730, doi: [10.1136/bmjopen-2012-001730](https://doi.org/10.1136/bmjopen-2012-001730), indexed in Pubmed: [23015603](https://pubmed.ncbi.nlm.nih.gov/23015603/).
22. Janz TG, Johnson RL, Rubenstein SD. Anemia in the emergency department: evaluation and treatment. *Emerg Med Pract*. 2013; 15(11): 1–15, indexed in Pubmed: [24716235](https://pubmed.ncbi.nlm.nih.gov/24716235/).
23. Kabata J, Hellmann A. Hemoglobina. In: Solnica B. ed. *Interna Szczeklika. Medycyna Praktyczna, Kraków* 2018: 1682.
24. Campbell NR, Hasinoff BB. Iron supplements: a common cause of drug interactions. *Br J Clin Pharmacol*. 1991; 31(3): 251–255, doi: [10.1111/j.1365-2125.1991.tb05525.x](https://doi.org/10.1111/j.1365-2125.1991.tb05525.x), indexed in Pubmed: [2054263](https://pubmed.ncbi.nlm.nih.gov/2054263/).
25. Li N, Zhao G, Wu W, et al. The efficacy and safety of vitamin c for iron supplementation in adult patients with iron deficiency anemia: a randomized clinical trial. *JAMA Netw Open*. 2020; 3(11): e2023644, doi: [10.1001/jamanetworkopen.2020.23644](https://doi.org/10.1001/jamanetworkopen.2020.23644), indexed in Pubmed: [33136134](https://pubmed.ncbi.nlm.nih.gov/33136134/).
26. Selected Revisions October 23, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
27. Pavord S, Myers B, Robinson S, et al. British Committee for Standards in Haematology. UK guidelines on the management of iron deficiency in pregnancy. *Br J Haematol*. 2012; 156(5): 588–600, doi: [10.1111/j.1365-2141.2011.09012.x](https://doi.org/10.1111/j.1365-2141.2011.09012.x), indexed in Pubmed: [22512001](https://pubmed.ncbi.nlm.nih.gov/22512001/).
28. Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. *BJOG*. 2006; 113(11): 1248–1252, doi: [10.1111/j.1471-0528.2006.01062.x](https://doi.org/10.1111/j.1471-0528.2006.01062.x), indexed in Pubmed: [17004982](https://pubmed.ncbi.nlm.nih.gov/17004982/).
29. Breyman C, Gliga F, Bejenariu C, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. *Int J Gynaecol Obstet*. 2008; 101(1): 67–73, doi: [10.1016/j.ijgo.2007.10.009](https://doi.org/10.1016/j.ijgo.2007.10.009), indexed in Pubmed: [18234203](https://pubmed.ncbi.nlm.nih.gov/18234203/).
30. Broche DE, Gay C, Armand-Branger S, et al. Severe anaemia in the immediate post-partum period. Clinical practice and value of intravenous iron. *Eur J Obstet Gynecol Reprod Biol*. 2005; 123(suppl. 2): S21–S27, doi: [10.1016/s0301-2115\(05\)80403-8](https://doi.org/10.1016/s0301-2115(05)80403-8).
31. Huang LL, Lee D, Troster SM, et al. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. *Nephrol Dial Transplant*. 2018; 33(9): 1628–1635, doi: [10.1093/ndt/gfx310](https://doi.org/10.1093/ndt/gfx310), indexed in Pubmed: [29165637](https://pubmed.ncbi.nlm.nih.gov/29165637/).
32. Miller HJ, Hu J, Valentine JK, et al. Efficacy and tolerability of intravenous ferric gluconate in the treatment of iron deficiency anemia in patients without kidney disease. *Arch Intern Med*. 2007; 167(12): 1327–1328, doi: [10.1001/archinte.167.12.1327](https://doi.org/10.1001/archinte.167.12.1327), indexed in Pubmed: [17592108](https://pubmed.ncbi.nlm.nih.gov/17592108/).
33. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. *Lancet*. 2007; 369(9572): 1502–1504, doi: [10.1016/s0140-6736\(07\)60689-8](https://doi.org/10.1016/s0140-6736(07)60689-8), indexed in Pubmed: [17482969](https://pubmed.ncbi.nlm.nih.gov/17482969/).
34. Fishbane S, Ungureanu VD, Maesaka J, et al. The safety of intravenous iron dextran in hemodialysis patients. *Am J Kidney Dis*. 1996; 28(4): 529–534, doi: [10.1016/s0272-6386\(96\)90463-1](https://doi.org/10.1016/s0272-6386(96)90463-1), indexed in Pubmed: [8840942](https://pubmed.ncbi.nlm.nih.gov/8840942/).
35. Torres S, Kuo YH, Morris K, et al. Intravenous iron following cardiac surgery does not increase the infection rate. *Surg Infect (Larchmt)*. 2006; 7(4): 361–366, doi: [10.1089/sur.2006.7.361](https://doi.org/10.1089/sur.2006.7.361), indexed in Pubmed: [16978079](https://pubmed.ncbi.nlm.nih.gov/16978079/).
36. Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. *PLoS One*. 2015; 10(2): e0117383, doi: [10.1371/journal.pone.0117383](https://doi.org/10.1371/journal.pone.0117383), indexed in Pubmed: [25700159](https://pubmed.ncbi.nlm.nih.gov/25700159/).
37. Goshorn J, Youell TD. Darbepoetin alfa treatment for post-renal transplantation anemia during pregnancy. *Am J Kidney Dis*. 2005; 46(5): e81–e86, doi: [10.1053/j.ajkd.2005.07.047](https://doi.org/10.1053/j.ajkd.2005.07.047), indexed in Pubmed: [16253714](https://pubmed.ncbi.nlm.nih.gov/16253714/).